On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
At a public meeting held on January 15, 2025, the Federal Trade Commission (FTC) summarized the Second Interim Staff Report ...
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
Zacks.com on MSN13d
FTC Report Reveals PBM Practices Impacting Competition and Drug CostsThe FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...
The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.
"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback